



## References

1. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. *J Neurosci*. 2001;21(23):9414-9418.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Published 2018. <https://www.psychiatry.org/psychiatrists/practice/dsm>. Accessed July 24, 2018.
3. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. *BMC Health Serv Res*. 2006;6:46.
4. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. *J Gen Intern Med*. 2002;17(3):173-179.
5. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. *J Pain Symptom Manage*. 2004;28(3):250-258.
6. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). *J Pain Symptom Manage*. 2006;32(3):287-293.
7. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med*. 2005;6(6):432-442.
8. National Institute on Alcohol Abuse and Alcoholism. Clinician's Guide to Helping Patients Who Drink Too Much. Published 2005. <https://pubs.niaaa.nih.gov/publications/practitioner/CliniciansGuide2005/guide.pdf>. Accessed June 25, 2018.
9. National Institute on Drug Abuse. Principles of Drug Addiction Treatment. A Research-Based Guide. Published 2012. [https://www.drugabuse.gov/sites/default/files/podat\\_1.pdf](https://www.drugabuse.gov/sites/default/files/podat_1.pdf). Accessed July 12, 2018.
10. Centers for Disease Control and Prevention. CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016. Published 2016. <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>. Accessed June 25, 2018.
11. Harm Reduction Coalition. Principles of Harm Reduction. Published 2018. <http://harmreduction.org/about-us/principles-of-harm-reduction>. Accessed June 26, 2018.
12. Boston University School of Public Health. The brief negotiated interview (BNI). Published 2018. <http://www.bu.edu/bniart/sbirt-in-health-care/sbirt-brief-negotiated-interview-bni/>. Accessed June 26, 2018.
13. Schuckit MA. Treatment of opioid-use disorders. *N Engl J Med*. 2016;375(4):357-368.
14. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*. 2003;361(9358):662-668.
15. Clark RE, Baxter JD, Awah G, O'Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history. *J Subst Abuse Treat*. 2015;57:75-80.
16. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. *N Engl J Med*. 2016;374(13):1232-1242.
17. Lee JD, Nunes EV, Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet*. 2018;391(10118):309-318.
18. US Food and Drug Administration. FDA briefing document. Joint Meeting of Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. October 31, 2017. Published 2017. <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrug-AdvisoryCommittee/UCM582447.pdf>. Accessed June 26, 2018.
19. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013;103(5):917-922.

20. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. *Am J Addict.* 2004;13(Suppl 1):S17-S28.
21. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Ann Intern Med.* 2018;doi:10.7326/M17-3107.
22. US Department of Health and Human Services. Facing Addiction in America. The Surgeon General's Report on Alcohol, Drugs, and Health. Published 2016. <https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf>. Accessed June 25, 2018.
23. Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: A scoping review. *Ann Intern Med.* 2017;166(4):268-278